Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI claim that severe hypocalcemia can occur in patients with advanced kidney disease (eGFR <30 mL/min/1.73 m2), including dialysis-dependent patients, after Prolia is directly supported by the provided label text (Sections 5.1 and 8.6).
Category Scores
Accurate Statements
Severe hypocalcemia can occur in patients with advanced kidney disease (e.g., eGFR <30 mL/min/1.73 m2), including dialysis-dependent patients, after Prolia administration.
Supported by Warnings/Precautions 5.1 and Renal Impairment 8.6 (increased risk of severe hypocalcemia in advanced CKD including dialysis-dependent patients following Prolia).
Unsupported Statements
Contradictions
Important Omissions
No mention that fatal cases have been reported (while not required to support the occurrence statement, it is present in the provided label text and could be considered material context).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The AI statement is a label-supported warning consistent with the prescribing information; it does not add unsupported risk or incorrect details.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor omission of label-specified severity context (fatal cases reported) that appears in the provided label excerpts.
Suggested Improvement
Optionally include that the label reports severe hypocalcemia with hospitalization, life-threatening events, and fatal cases in advanced CKD (eGFR <30 mL/min/1.73 m2) including dialysis-dependent patients.